{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:15:50Z","timestamp":1761956150173,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1053\/j.seminhematol.2009.01.010","type":"journal-article","created":{"date-parts":[[2009,4,2]],"date-time":"2009-04-02T04:48:57Z","timestamp":1238647737000},"page":"S16-S21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"S3","title":["Practical Considerations for the Management of Patients in the Tyrosine Kinase Inhibitor Era"],"prefix":"10.1053","volume":"46","author":[{"given":"Michael","family":"O'Dwyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehab","family":"Atallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2009","series-title":"NCCN: Clinical practice guidelines in oncology","key":"10.1053\/j.seminhematol.2009.01.010_bib1"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib2","doi-asserted-by":"crossref","first-page":"15a","DOI":"10.1182\/blood.V110.11.25.25","article-title":"IRIS 6-year follow-up: sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"110","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib4","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib5","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib6","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","article-title":"Practical management of patients with chronic myeloid leukemia receiving imatinib","volume":"21","author":"Deininger","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib7","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1634\/theoncologist.9-3-271","article-title":"Indications for imatinib mesylate therapy and clinical management","volume":"9","author":"Guilhot","year":"2004","journal-title":"Oncologist"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib9","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","article-title":"Altered bone and mineral metabolism in patients receiving imatinib mesylate","volume":"354","author":"Berman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib10","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1182\/blood-2007-07-104281","article-title":"Long-term imatinib therapy promotes bone formation in CML patients","volume":"111","author":"Fitter","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib11","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3324\/haematol.12373","article-title":"Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia","volume":"93","author":"Jonsson","year":"2008","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib12","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/blood.V108.11.2136.2136","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib13","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib14","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood-2007-04-038943","article-title":"How I treat chronic myeloid leukemia in the imatinib era","volume":"110","author":"Goldman","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib15","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib16","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant BCR-ABL","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib18","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-04-2601","article-title":"AMN107, a novel aminopyrimidine inhibitor of BCR-ABL, has in vitro activity against imatinib-resistant chronic myeloid leukemia","volume":"11","author":"Golemovic","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib19","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2009.01.010_bib20","first-page":"56","article-title":"Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukaemia (CML) in chronic phase (CP) or accelerated phase (AP)","volume":"93","author":"Hochhaus","year":"2008","journal-title":"Hematologica"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib21","doi-asserted-by":"crossref","first-page":"387s","DOI":"10.1200\/jco.2008.26.15_suppl.7063","article-title":"Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) or accelerated phase (AP)","volume":"26","author":"Jabbour","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2009.01.010_bib22","first-page":"51","article-title":"Dasatinib lack of cross intolerance to imatinib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) who are intolerant to imatinib\u2014a retrospective safety analysis","volume":"93","author":"Guilhot","year":"2008","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib23","doi-asserted-by":"crossref","first-page":"375s","DOI":"10.1200\/jco.2008.26.15_suppl.7015","article-title":"Dasatinib lack of cross intolerance to imatinib in patients with chronic myelogenous leukemia chronic phase (CML-CP) intolerant to imatinib: A retrospective analysis of safety","volume":"26","author":"Khoury","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib24","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia","volume":"111","author":"le Coutre","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib25","doi-asserted-by":"crossref","unstructured":"le Coutre P, O'Dwyer M, Mendes W, Woodman R. The occurrence of pleural\/pericardial effusions in Ph+ CML patients failing prior tyrosine kinase inhibitors (TKI) before starting nilotinib \u2013 analysis of data from compassionate use program Hematologica. 2008;93 Suppl 1:226.","DOI":"10.1182\/blood.V112.11.4271.4271"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2009.01.010_bib26","first-page":"372","article-title":"Dasatinib long-term efficacy in patients with chronic myeloid leukemia in chronic phase (CML-CP) with resistance or intolerance to imatinib: a two-year update of the START-C study","volume":"93","author":"Cervantes","year":"2008","journal-title":"Haematologica"},{"issue":"Suppl","key":"10.1053\/j.seminhematol.2009.01.010_bib27","first-page":"374s","article-title":"Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C)","volume":"26","author":"Mauro","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib28","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":"Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment","volume":"111","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib30","first-page":"24","article-title":"Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM) [abstract 6119]","author":"Tsang","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib31","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving a molecular response","volume":"104","author":"Cortes","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib32","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib33","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.010_bib34","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196309000213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196309000213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:19:25Z","timestamp":1758521965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196309000213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":33,"alternative-id":["S0037196309000213"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2009.01.010","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2009,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical Considerations for the Management of Patients in the Tyrosine Kinase Inhibitor Era","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2009.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}